New Medicare reform has led to the coverage Humira, Abbott's top selling RA medication. This will lead to an increase in sales and allow Humira to shift market share away from its new competitors in the Medicare market, Remicade and Enbrel.
Abbott is awaiting FDA approval for additional indications of Humira. After excellent clinical trials for new indications, Humira will be a threat to the existing competition. If Humira is approved for more indications, its sales are expected to double within the next few years.
Abbott's Xience V drug-eluting stent has had very successful late-stage clinical trials. If approved by the FDA, Xience V is projected to take over the multi-billion dollar DES market and prove to be highly profitable to Abbott.
The proceeds will be reinvested in external and organic growth with a sharp focus on long term value creation. Abbott sees the partnership as a way to expand into emerging markets in Eastern Europe and Asia, where Abbott had limited presence
